How Has the Liver Cancer Diagnostics Market Evolved Historically and What is its Current Size?
The liver cancer diagnostics market has seen considerable growth due to a variety of factors.
•The market size for liver cancer diagnostics has seen significant growth in the past few years. There is an anticipated increase from $9.69 billion in 2024 to $10.4 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%.
The previous growth can be credited to advances in biopsy techniques and histopathology, along with the development of biomarker detection. Additionally, progress in screening programs, enhancements in genetic testing, and improved liver imaging modalities have also contributed to this growth.
What is the Forecasted Market Size and CAGR for the Liver Cancer Diagnostics Market?
The liver cancer diagnostics market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size for liver cancer diagnostics is anticipated to experience robust growth. The market is projected to reach "$13.86 billion by 2029, with a compound annual growth rate (CAGR) of 7.4%.
Factors contributing to this growth during the forecast period include changes in regulations and standardization, the increasing significance of imaging modalities, the advancement of next-generation sequencing, the expansion of screening platforms and awareness, and the growing demand for biomarker-based testing. Notable trends for the forecast period encompass the rise in incidence and prevalence, improvements in imaging technologies, emphasis on non-invasive diagnostics, precision medicine, personalized diagnostics, and the incorporation of artificial intelligence (AI).
What Key Factors and Trends are Driving the Growth of the Liver Cancer Diagnostics Market?
The increasing occurrence of liver cancer is anticipated to fuel the expansion of the liver cancer diagnostics market. Liver cancer is a condition where there is an uncontrolled growth and multiplication of liver cells that results in a serious health risk. These diagnostic tests for liver cancer are used to verify if cancer cells are multiplying within the liver or surrounding it after the primary liver carcinoma has been diagnosed. Thus, the growing incidence of liver cancer escalates the demand in the liver cancer diagnostics market. For example, in January 2023, the American Cancer Society, a volunteer health organization based in the US, released the Cancer Facts & Figures 2023 report which stated that the new cases of liver and intrahepatic bile duct cancer in women had risen to 13,230 in 2023 from 12,640 in 2020 in the United States. In addition, it is projected that 41,210 new cases of liver cancer will be detected in the US in 2023, with an anticipated death toll of 29,380 individuals. Thus, the escalating occurrence of liver cancer is stimulating the expansion of the liver cancer diagnostics market.
What are the Market Segments in the Liver Cancer Diagnostics Market?
The liver cancer diagnostics market covered in this report is segmented –
1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Other Types
2) By Screening: Laboratory Testing, Imaging, Endoscopy, Biopsy, Other Screenings
3) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies
4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And CRO Laboratories
Subsegments:
1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma
2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
3) By Hepatoblastoma: Pure Hepatoblastoma, Mixed Hepatoblastoma
4) Other Types: Secondary Liver Cancer, Fibrolamellar Carcinoma
Pre-Book The Liver Cancer Diagnostics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Liver Cancer Diagnostics Market?
Key players in the liver cancer diagnostics market are innovating with advanced assays and algorithms based on biomarkers to enhance diagnostic accuracy and facilitate early detection. These biomarker-based assays and algorithms are diagnostic instruments that use specific biological indicators for disease identification, lending greater precision and efficiency to diagnostic processes. For example, Roche Diagnostics, an American biotech firm, introduced the Elecsys PIVKA-II assay and Elecsys GAAD algorithm in November 2023. The Elecsys PIVKA-II assay registers increased levels of the PIVKA-II biomarker, linked to hepatocellular carcinoma (HCC), thereby improving early detection of liver cancer in patients at high-risk. The Elecsys GAAD algorithm amalgamates multiple diagnostic markers, including PIVKA-II and AFP, in order to sharpen diagnostic accuracy and streamline the decision-making process in liver cancer detection.
Who Are the Key Players in the Liver Cancer Diagnostics Market?
Major companies operating in the liver cancer diagnostics market include:
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Qiagen NV
• Thermo Fisher Scientific Inc.
• Siemens Healthineers
• Illumina Inc.
• Koninklijke Philips NV
• Epigenomics AG
• Digna Biotech SL
• Biocept Inc.
• Danaher Corporation
• Foundation Medicine Inc.
• Agilent Technologies Inc.
• Genemed Biotechnologies Inc.
• Merck KGaA
• Fujifilm Medical Systems USA Inc.
• GE Healthcare
• Advanced Cell Diagnostics Inc.
• Oxford Gene Technology
• Leica Biosystems Nussloch GmbH
• Exiqon A/S
• BioGenex Laboratories Inc.
• OncoCyte Corporation
• Guardant Health Inc.
• Exact Sciences Corporation
• Grail Inc.
• Freenome Holdings Inc.
• Natera Inc.
• Personal Genome Diagnostics Inc.
• Thrive Earlier Detection Corp
What are the Regional Insights into the Liver Cancer Diagnostics Market?
North America was the largest region in the liver cancer diagnostics market in 2024. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
